enVVeno (NVNO): Debts to Book Capitalization

Brandmark of enVVeno Medical Corporation (NVNO)

Geopolitical fractures and sanctions are hindering the expansion of innovative valves, which limits dividend potential for enVVeno Medical (NVNO). The percentage of debt participation in balance sheet capital serves as a resilience indicator, where the value of 0.02 corresponds to the current metric. enVVeno Medical (NVNO) attracts bioengineers with generous stock options to develop venous implants, while adhering to strict purity standards and minimizing plastic packaging.

NVNO - enVVeno Corp Debts to Net Assets over the range 07/04/2022 - 10/29/2026
Original product of enVVeno Medical Corporation

The uniqueness of the VenoValve bioprosthesis and the strong pricing power of enVVeno Medical (NVNO) necessitate precise financial leverage management. This indicator measures the proportion of borrowed funds relative to equity, determining the company's dependence on creditors. Analyzing the structure of debt obligations relative to book capitalization helps identify default risks or the underutilization of capital. A decrease in this ratio minimizes volatility but may limit asset returns. A stable trend confirms the efficiency of resource allocation prior to product commercialization.

Competitors of enVVeno Medical

BSX: Debts to Book Capitalization|Debts to Book Value edwards.com EW|RMD: Debts to Book Capitalization|PODD - Debt to Book Value|Zimmer Biomet - Debts to Book Capitalization|CooperSurgical (COO) - Debts to Net Assets|ALGN (Align Technology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization GMED|Debt to Book Capitalization Ratio TransMedics Organ Care System (TMDX)|Debt to Book Capitalization Ratio Alphatec Holdings (ATEC)|Debts to Book Capitalization AORT|ENOV - Debts to Net Assets|Debt to Book Value Integra LifeSciences|ESTA - Debts to Book Capitalization Ratio|Debts to Book Capitalization BBNX|IRADIMED Corp (IRMD) - Debts to Book Value|Debts to Book Capitalization Embecta Inc. (EMBC)|Debt to Book Value Ratio Tandem Corp (TNDM)|AxoGen, Inc. (AXGN) - Debt to Book Value|Debt to Net Assets Ratio SIBN (si-bone.com)|Orthofix - Debt to Book Capitalization Ratio|Debt to Book Value Bioventus Inc BVS|KIDS (OrthoPediatrics Inc.) - Debts to Book Capitalization|TMCI - Debts to Book Value|Debts to Book Capitalization Strata Critical Medical Inc|carlsmed.com (CARL) - Debt to Book Value Ratio|RXST: Debts to Book Capitalization|Debts to Net Assets ClearPoint|Debts to Book Capitalization STXS (Stereotaxis Corp)|Debt to Book Value Neuronetics, Inc (STIM)|Debts to Book Capitalization SGHT (Sight Sciences, Inc.)|Orchestra BioMed Inc. - Debts to Book Capitalization|ANIK - Debt to Book Capitalization Ratio|InspireMD Inc (NSPR) - Debt to Book Capitalization Ratio|Debt to Book Value zhjmedical.com ZJYL|Vivani Medical (VANI) - Debt to Net Assets Ratio|Debts to Book Capitalization XTNT (Xtant Medical Holdings, Inc.)|Debts to Book Value NMTC|MODD: Debt to Book Capitalization Ratio|Debt to Net Assets Myomo Inc. MYO|Debt to Book Value COCH (Envoy Medical, Inc)|Debts to Book Capitalization Vivos Therapeutics Inc VVOS|Debts to Book Capitalization SINT (SINTX Technologies)|TNON: Debts to Net Assets|Debt to Book Capitalization Ratio Lifeward (LFWD)|AMIX (Autonomix Medical) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio IVF|Debt to Book Value Bone Biologics Inc|Axonics, Inc. - Debts to Book Capitalization|Debts to Book Value BIOL (biolase.com)|DYNT - Debt to Book Capitalization Ratio|FNA - Debt to Book Value Ratio|Debt to Book Value INVO Bio INVO